Heated humidified high-flow nasal cannula; high-flow tracheal oxygen; conventional oxygen therapy; tracheostomy cuff; early cuff deflation Heated humidified high-flow oxygen therapy, administered using a nasal cannula, is called high-flow nasal cannula (HFNC). HFNC has been introduced and is used as a respiratory support mode in patients with respiratory disorders. HFNC is widely used in adults [1,2], children [3], and neonates [4,5]. The use of HFNC in current clinical practice is supported by evidence. However, current knowledge on the effects of high-flow tracheal oxygen (HFT) remains inconclusive. HFNC provides sufficient levels of both oxygen and airway humidity with a higher gas flow of up to 60 L/min [1,2]. Because of these advantages, HFNC has been a widely used device for when patients need respiratory support. HFNC has exhibited clinical benefits in hypoxemic respiratory failure [6-9], as an alternative to noninvasive ventilation [10], in post-extubation care [11], and in exercise training [12]. HFT can be delivered at a heated humidified high-flow mode as HFNC. However, the outcomes of HFNC use may not directly translate to those of HFT use. Both the mechanism of action and physiological effects appear different and require further investigation [13-15]. In the present editorial, we discuss the state of the art in HFT use, focusing on the practical use of HFT and the body of clinical evidence.